Myelofibrosis

Myelofibrosis is a rare, chronic blood cancer in which scar tissue builds up in the bone marrow. The scarring disrupts normal blood-cell production, which can lead to low or abnormal levels of red blood cells, white blood cells, and platelets. Primary myelofibrosis begins on its own, while secondary myelofibrosis develops after another blood disorder, such as polycythemia vera or essential thrombocythemia. It can affect adults of different ages, although it is more common later in life.

Myelofibrosis begins with acquired changes in blood-forming stem cells in the bone marrow. These changes can send abnormal signals that cause the marrow to produce blood cells incorrectly and can promote progressive buildup of scar tissue. As the marrow becomes less effective, the spleen and sometimes the liver may help make blood cells.

Primary and Secondary Myelofibrosis

Primary myelofibrosis develops without a preceding blood disorder. Secondary myelofibrosis develops after another myeloproliferative neoplasm, most often polycythemia vera or essential thrombocythemia. Testing may identify mutations such as JAK2, CALR, or MPL, but the exact initiating cause is often unknown. These changes are usually acquired rather than inherited, and myelofibrosis is not usually caused by lifestyle choices.

A complete blood count and blood smear can show anemia, unusual white blood cells, platelet changes, or immature blood cells circulating in the bloodstream. These findings can raise concern about myelofibrosis, but they do not confirm the diagnosis by themselves. Doctors interpret the results alongside symptoms, physical examination findings, and other tests.

Bone Marrow Testing

A bone marrow aspiration and biopsy examine the marrow directly. They can identify the degree and pattern of fibrosis and help exclude other blood disorders that may cause similar blood-count changes. Molecular and cytogenetic testing may look for mutations such as JAK2, CALR, and MPL, as well as chromosome changes. Ultrasound or other imaging can assess enlargement of the spleen and liver.

Medicines and Symptom-Directed Treatment

JAK inhibitors and other medicines may reduce symptoms, improve blood counts, or shrink an enlarged spleen in appropriate patients. Additional treatments may target anemia, constitutional symptoms such as fever and night sweats, itching, or spleen-related discomfort. Supportive care can include blood transfusions, growth-factor approaches, and iron or vitamin treatment when testing shows they are needed. Doctors also monitor and manage infections, bleeding, and clotting risk.

Allogeneic Stem-Cell Transplant

An allogeneic stem-cell transplant replaces diseased blood-forming cells with healthy cells from a donor. It is an intensive treatment that may offer the only potential cure for carefully selected patients, but it also carries serious risks, including infections, organ complications, and graft-versus-host disease. Eligibility depends on factors such as disease risk, age, overall health, available donor options, and the person’s treatment goals.

Myelofibrosis may progress slowly for years in some people, while it can cause serious complications more quickly in others. Myelofibrosis prognosis depends on clinical findings, blood counts, genetic and chromosome results, symptoms, response to treatment, and overall health. Regular follow-up helps the care team identify changes and adjust treatment goals.

How Prognosis Is Estimated

Prognostic scoring may consider age, constitutional symptoms, anemia or other blood-count changes, the number of immature cells circulating in the blood, chromosome findings, and molecular features. These categories provide a framework for discussing treatment and monitoring; they cannot predict exactly what will happen to one person. A hematologist can explain how individual results affect outlook.